The cell and gene therapy (CGT) market has captured the imagination of investors, healthcare professionals, and patients alike with promises of revolutionary treatments that could cure previously untreatable diseases. Recent market projections suggest the sector could reach USD 232.22 billion by 2035, growing at a remarkable 24% compound annual growth rate (CAGR). But as someone who has followed biotech markets for over a decade, I've learned that extraordinary projections demand extraordinary scrutiny—and the CGT market is no exception.

The Promise and the Projections

Cell and gene therapies represent a paradigm shift in medicine. Unlike traditional pharmaceuticals that treat symptoms, these therapies aim to cure diseases at their genetic or cellular root. CAR-T cell therapies like Kymriah and Yescarta have already demonstrated remarkable efficacy in certain blood cancers, offering hope where conventional treatments have failed. Gene therapies are addressing rare genetic disorders that once had no treatment options whatsoever.

The optimistic USD 232.22 billion projection, appearing in multiple market research reports, assumes a baseline market value of approximately USD 27 billion in 2025. This would represent nearly a nine-fold increase over the next decade—an impressive trajectory by any measure. The excitement is understandable: we're witnessing the early stages of what could become medicine's next major revolution.

However, my analysis of multiple market research sources reveals significant discrepancies that should give investors and industry stakeholders pause. While some analysts project USD 232 billion by 2035, others estimate more conservative figures of USD 172.22 billion (at 23.17% CAGR), USD 108.09 billion by 2032 (at 35.09% CAGR), or even USD 39.61 billion by 2034 (at 17.98% CAGR). These aren't minor variations—they represent fundamentally different assessments of the market's trajectory.

Understanding the Discrepancies

Why such dramatic differences? Having evaluated numerous biotech market reports, I can identify several key factors driving these disparities:

Methodological Variations: Different research firms employ distinct methodologies. Some include only approved therapies in their calculations, while others factor in pipeline products with varying probability adjustments. The definition of what constitutes "cell and gene therapy" itself varies—some reports separate cell therapy from gene therapy, while others combine them. The distinction between ex-vivo (cells modified outside the body) and in-vivo (direct genetic modification) approaches further complicates comparisons.

Regional Scope Differences: Market projections vary significantly based on geographic coverage. Global estimates differ from those focused on North America, Europe, or Asia-Pacific markets individually. Given that regulatory environments, reimbursement structures, and healthcare infrastructure vary dramatically across regions, this geographical scope profoundly impacts projections.

Base Year Assumptions: The variance in baseline valuations is striking—ranging from USD 8.94 billion to USD 27 billion for 2025. This discrepancy alone accounts for much of the divergence in future projections. These baseline differences likely reflect different inclusion criteria: are researchers counting only commercialized therapies, or including clinical-stage programs? Are they measuring revenues, market value, or total investment?

Optimism Bias in Press Releases: The highest projections often appear in press-release style reports designed to generate attention. As an industry analyst, I've observed that syndicated market research reports distributed through newswires tend toward the optimistic end of the spectrum, potentially inflating expectations.

The Reality Check: Challenges Ahead

While I remain genuinely excited about CGT's potential, several substantial obstacles could constrain growth below the most optimistic projections:

Manufacturing Complexity and Cost: Current CGT manufacturing processes are extraordinarily complex and expensive. Personalized CAR-T therapies require extracting a patient's cells, genetically modifying them in specialized facilities, and reinfusing them—a process costing hundreds of thousands to over a million dollars per patient. Scaling this model to treat millions of patients presents formidable challenges. Until manufacturing becomes more standardized and cost-effective, market penetration will remain limited.

Regulatory Hurdles: While the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation has accelerated some approvals, regulatory pathways remain complex and lengthy. Each therapy must demonstrate not only efficacy but also long-term safety—a particularly challenging requirement for treatments that permanently alter patients' genetic material. Regulatory setbacks can delay market entry by years and dramatically impact projections.

Reimbursement Challenges: Even approved therapies face significant reimbursement hurdles. Payers struggle with the economics of treatments that cost $500,000 to $2 million upfront, even if they potentially eliminate the need for years of conventional therapy. Novel payment models—including outcomes-based contracts and annuity-style payments—are emerging, but widespread adoption remains uncertain.

Competition and Market Saturation: As more CGT products enter the market, competition will intensify. Multiple CAR-T therapies now target similar indications, and gene therapies for the same genetic disorders are being developed by competing firms. This competition, while beneficial for patients, will likely compress margins and slow revenue growth for individual companies.

What This Means for Stakeholders

For investors, the message is clear: approach CGT investments with both enthusiasm and caution. The sector offers genuine opportunities, but the wide variance in market projections suggests significant uncertainty. Diversification across multiple companies and therapeutic approaches can mitigate risk. Focus on companies with strong manufacturing capabilities, diverse pipelines, and realistic paths to profitability rather than chasing the highest growth projections.

For healthcare systems and payers, preparation is essential. Even conservative growth projections suggest CGT will become increasingly important. Developing appropriate reimbursement frameworks, building expertise in outcomes assessment, and creating infrastructure to support these complex therapies will be critical.

For patients and advocacy groups, the CGT revolution offers genuine hope, but tempering expectations with realism remains important. Not every promising therapy will succeed, and access challenges will likely persist for years.

Conclusion: Navigating the Hype Cycle

The cell and gene therapy market stands at a critical juncture. The science is real, the clinical results are often remarkable, and the long-term potential is genuinely transformative. However, the path from today's USD 20-30 billion market to a potential USD 200+ billion market by 2035 is neither straight nor guaranteed.

The dramatic variance in market projections—from under USD 40 billion to over USD 230 billion—reflects genuine uncertainty about how quickly manufacturing will scale, how effectively regulatory and reimbursement challenges will be addressed, and how many pipeline therapies will successfully reach patients. Rather than accepting any single projection as gospel, stakeholders should scenario-plan across a range of outcomes.

My assessment? The truth likely lies somewhere between the most conservative and most optimistic projections. CGT will grow substantially and transform treatment paradigms for numerous diseases, but probably not as quickly or completely as the highest projections suggest. The companies that succeed will be those that solve the manufacturing, regulatory, and reimbursement challenges while maintaining scientific rigor and realistic expectations.

The CGT revolution is real—but revolutions rarely follow predictable timelines or linear growth curves. Understanding both the potential and the pitfalls will separate successful stakeholders from those caught up in the hype cycle.